Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Slides:

Advertisements

Similar presentations

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

Advertisements

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.

Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Follicular Variant of Papillary Thyroid Cancer: Encapsulated,

CtDNA NGS testing identified a high-level MET amplification (copy number of 53.6 in circulation) (Figure 1A). The test was repeated on a second tube of.

Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.

8th Mucscat International Oncology conference. Muscat, Oman

Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.

Copyright © 2010 American Medical Association. All rights reserved.

Presented By Michael Lee at 2016 ASCO Annual Meeting

Christopher S. Lathan, M. D. , M. S. , M. P. H

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Dose-escalation patient response.

Challenges in RAS Wild-Type mCRC

The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Colorectal Cancer: Current “Standard” Uses for Molecular Testing

Figure 3 Monitoring clonal evolution using liquid biopsies

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?

A, baseline and 4-week PET scan from patient 2 (MET c

Revealing the genomic heterogeneity of melanoma

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Progress of the NSCLC Revolution

Progression-Free Survival Times Overall Survival Times

Published online September 20, 2017 by JAMA Surgery

Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.

New Insights on Treatment Strategies for mCRC:

Raymond N. DuBois, M.D., Ph.D. Executive Director

Ali Shamseddine,MD,FRCP

Proposed spiral model for prostate cancer progression.

Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal.

Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.

Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. Treatment.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Development of 28 public molecular laboratories in France for molecular testing. Development of 28 public molecular laboratories in France for molecular.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations.

MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification.

Location of common clinically relevant mutations in EGFR

Heterogeneous effects of fulvestrant were observed between lesions within individuals. Heterogeneous effects of fulvestrant were observed between lesions.

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

Location of the ER mutations and frequencies per cohort.

p53 loss affects several steps of the metastatic process.

Combined inhibition of coamplified RTKs is required for response.

Frequent coamplification of RTKs in MET-amplified EGC

Possible outcomes of therapeutic treatments using the spiral model.

Representative patient responses to ulixertinib.

Rapid autopsy reveals interlesional and intralesional heterogeneity of resistance. Rapid autopsy reveals interlesional and intralesional heterogeneity.

Genetic analysis suggests the presence of four clinically relevant groups of histologically defined anaplastic oligodendrogliomas. Genetic analysis suggests.

Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.

Serial CT scan images from patient with a partial response.

Concordance between liquid versus tissue biopsies.

Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies.

Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.

Figure 1. Heterogeneous HER2 immunostaining in two gastric cancer samples classified as HER2 3+. (A) Complete ... Figure 1. Heterogeneous HER2 immunostaining.

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Presentation transcript:

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Response to anti-EGFR targeted therapies in mCRC is accompanied by selection of preexisting resistant clones present in the initial metastasis burden. Conceivably, resistant clones can also emerge during treatment. Clones carrying distinct molecular alterations such as KRAS, NRAS, EGFR, and BRAF mutations or KRAS, HER2, or MET amplifications can coexist in the same metastatic site or in different metastatic sites. CT scans were obtained from a colorectal cancer patient who showed the first response to cetuximab observed at Ospedale Niguarda Ca' Granda in 2001. Sandra Misale et al. Cancer Discovery 2014;4:1269-1280 ©2014 by American Association for Cancer Research